Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDKN2A interacting protein N-terminal like pseudogene 2 (CDKN2AIPNLP2) is classified as a pseudogene, meaning it is a DNA segment that resembles a gene but is generally nonfunctional and does not encode a protein[1][4][8]. There is no evidence that this pseudogene has a protein or RNA function, nor is it implicated as a drug target or as a regulator in disease. Pseudogenes as a class may sometimes influence gene expression or genomic regulation, but no such role has been demonstrated for CDKN2AIPNLP2. It should not be considered a molecular target for therapeutic development[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDKN2A interacting protein N-terminal like pseudogene 2 (CDKN2AIPNLP2).